Abuse Deterrent Formulations Market

Opioid abuse deterrent formulations are estimated at 54.0% by product in 2026, with chronic pain management at 49.0% and hospitals at 46.0%. Adoption depends on route-specific deterrence that preserves therapeutic release, although controlled access and limited payer premiums restrict wider commercial use.